API-2-Induced Cell Migration Is Overcome by Small Molecular Approaches Inhibiting β-Catenin

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• Advanced colorectal cancer (CRC) frequently involves Adenomatous Polyposis Coli (APC) mutations (90%).
• APC mutations lead to simultaneous activation of Wnt/β-catenin and AKT signaling pathways.
• Current AKT inhibitors face limitations in CRC treatment due to nuclear β-catenin-induced epithelial-mesenchymal transition (EMT) and apoptosis evasion.

Purpose of the Study:

• To investigate a combinatorial therapeutic strategy for advanced colorectal cancer.
• To overcome the limitations of existing AKT inhibitors in CRC treatment.
• To evaluate the efficacy of targeting both AKT and Wnt/β-catenin pathways simultaneously.

Main Methods:

• Utilized an AKT inhibitor (API-2) in combination with a novel β-catenin destabilizer (KY1022).
• Assessed the impact of combinatorial treatment on nuclear β-catenin levels.
• Evaluated the effects on EMT and apoptosis in CRC models.

Main Results:

• The combination of an AKT inhibitor and KY1022 effectively reduced nuclear β-catenin levels.
• This combinatorial approach overcame the limitations associated with API-2 monotherapy.
• Simultaneous suppression of Wnt/β-catenin and AKT signaling pathways was demonstrated.

Conclusions:

• Simultaneous suppression of Wnt/β-catenin and AKT signaling pathways is a promising strategy for advanced CRC.
• This approach can overcome AKT-inhibitor-mediated metastasis and enhance therapeutic efficacy.
• Combinatorial treatment with AKT inhibitors and β-catenin destabilizers offers a potential new avenue for CRC therapy.